CRM197 is commonly used as a carrier protein in protein-polysaccharide conjugation, and CRM197 has many advantages over other carrier proteins, i.e. diphtheria toxoid or tetanus toxoid proteins. Our rCRM197 can be mass-produced from genetically modified E. coli at higher yield. It is currently used for the development of Typhoid Conjugate Vaccine (TCV), Meningococcal Conjugate Vaccine (MCV), and Pneumococcal Conjugate Vaccine (PCV) under development.
|Product Name||Immune-Enhancing Carrier protein, rCRM197|
|Product Purpose||For research purpose and at GMP grade for vaccine development|
|Usage||Carrier protein enhancing the immunogenicity|